ACC will hold a meeting of the Board of Directors of the Company on 28 January 2025.

Adani Ports & Special Economic Zone announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 2 February 2026.

Affle 3i has allotted 44,250 equity shares of Rs. 2 each on January 12, 2026, to Affle (India) Limited Employees' Welfare Trust under Affle (India) Limited Employee Stock Option Scheme – 2021.

Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs. 281,514,768/- divided into 140,757,384 equity shares of Rs. 2/- each.

Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 30 January 2026.

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its supplemental Abbreviated New Drug Application (sANDA) Bosutinib Tablets, 400 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Bosulif Tablets, 400 mg, of PF Prism C.V. (PF Prism C.V.). Bosutinib is a kinase inhibitor indicated for the treatment of i) adult patients with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy, and ii) adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.

Alembic had previously received final approval for its ANDA Bosutinib Tablets, 100 mg and 500mg. Refer label for a detailed indication.

Bosutinib Tablets, 400 mg, have an estimated market size of US$ 251 million for twelve months ending September 2025 according to IQVIA.

Alembic has a cumulative total of 232 ANDA approvals (212 final approvals and 20 tentative approvals) from USFDA.

Ambuja Cements will hold a meeting of the Board of Directors of the Company on 30 January 2026.

The board of Anand Rathi Wealth at its meeting held on 12 January 2026 has approved shifting of Registered Office of the Company from Floor No. 10, A wing, Express Zone, Western Express Highway, Goregaon (East), Mumbai – 400 063 to Floor No. 2, Block B & C, E wing, Trade Link, Kamala Mills Compound, Senapati Bapat Marg, Lower Parel, Mumbai – 400 013 effective from 12 January 2026.

Atishay will hold a meeting of the Board of Directors of the Company on 19 January 2026.

Aurionpro Solutions announced another significant order from Delhi Metro Rail Corporation (DMRC) for the implementation of Automated Fare Collection (AFC) systems for the Bhopal and Indore Metro Rail projects.

As part of DMRC's collaboration with Madhya Pradesh Metro Rail Corporation (MPMRCL), the project aims to deploy standardized AFC systems to enhance commuter convenience, operational efficiency, and interoperability across the upcoming metro networks in Madhya Pradesh. Under this multi-year contract, valued at approximately Rs 150 crore, Aurionpro will supply, implement, and maintain open-loop EMV card- and QR-code-based AFC solutions for both metro projects. The scope of work spans end-to-end implementation followed by comprehensive maintenance and support services over a five-year period, further reinforcing Aurionpro's strong credentials and growing leadership in India's smart transit ecosystem.

Aurionpro's automated solutions streamline fare collection and are platformed on open-loop and closed-loop EMV ticketing architecture, aligned as per global payment compliances, and in India, as per the NCMC norms. Backed by a fully integrated in-house design and manufacturing ecosystem, Aurionpro delivers globally compliant, high-quality solutions that are designed and made in India.

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 16 January 2026.